Cinacalcet will be approved when the following is met:

1. The patient has ONE of the following:
   1. A diagnosis of hypercalcemia due to parathyroid carcinoma 
      OR
   2. A diagnosis of primary hyperparathyroidism (HPT) AND BOTH of the following:
      1. The patient has a pretreatment serum calcium level that is above the testing laboratory’s upper limit of normal 
         AND
      2. The patient is unable to undergo parathyroidectomy
         OR
   3. Another indication that is FDA approved or supported in CMS approved compendia for the requested medication not otherwise excluded from Part D [i.e., secondary hyperparathyroidism due to end-stage renal disease (ESRD) on dialysis]

NOTE: The use of cinacalcet for the diagnosis of secondary hyperparathyroidism (HPT) due to endstage renal disease (ESRD) on dialysis is not a Medicare Part D eligible indication but is coverable under Medicare Part B from the covered uses.

Length of approval: 12 months